Table 4.
The reported clinical trials using MSCs from AT, BM, and UC in the treatment of cardiovascular diseases
| Year | Disease | MSC source | No. of treated patients | Efficacy |
|---|---|---|---|---|
| 2013307 | Heart failure | BM | 21 | - Improvement in LVEF and MLHFQ |
| - Decrease in LVESV and LVEDV | ||||
| - Increase in 6MWT | ||||
| - No evidence of increased cardiac or systemic toxicity | ||||
| 2017308 | Ischemic heart failure | BM | 120 | - Improvement in LVEF, ESV, LEVDV, and MLHFQ |
| 2012309 | ischemic cardiomyopathy | BM | 30 | - Functional improvement (change in 6MWT, MLHFQ, and NYHA classification) |
| 2017310 | Nonischemic Dilated Cardiomyopathy | BM | 34 | - Increase in 6MWT, ejection fraction |
| - Improvement in MLHFQ | ||||
| - Reduction in inflammatory cytokine, TNF-a | ||||
| 2015311 | Severe ischemic heart failure | BM | 60 | - Significant Improvement in LVEF, ESV, stroke volume, and myocardial mass. No difference in NYHA class, 6MWT, and Kansas City cardiomyopathy questionnaire after 6-month follow-up |
| 2020312 | Severe ischemic heart failure | BM | 60 | - Significant improvements in LVEF, LVESV, stroke volume and myocardial mass. Significant reduction in the amount of scar tissue and quality of life score after 12 months’ of follow-up. |
| - Significantly fewer hospitalizations for angina after 4 years of follow-up | ||||
| 2017313 | Ischemic Cardiomyopathy | BM | 30 | - Reduction in scar size |
| - Increase in ejection fraction when using 100 million dose | ||||
| 2021314 | Ischemic heart failure | BM | 25 | - Improvement in clinical outcomes, including MACE and quality of life |
| - No improvement in LVEF, left ventricular, scar size, 6MWT, and oxy peak oxygen consumption did not differ between groups | ||||
| 2013315 | ischemic cardiomyopathy | BM | 19 | - Improvement in MLHF, 6MWT, regional myocardial function |
| - No change in ejection fraction and left ventricular chamber volume | ||||
| 2014316 | Chronic ischemic cardiomyopathy | AD | 21 | - No significant change in LVEF, SPECT, and rest total severity score |
| - Increase in LV total mass | ||||
| - Improvement in WMSI | ||||
| - Preserved MVO2 and METs | ||||
| 2017318 | Chronic myocardial ischemia | AD | 15 | - Significant improvement in LVEF, ESV, LEVDV, and MLHFQ |
| 2017319 | Ischemic heart failure | AD | 10 | - Improvement in LVEF, LVSEV, 6MWT, NYHA class |
| - No difference in KKCQ scores and CCS class | ||||
| 2017320 | Chronic Ischemic Heart Disease | AD | 41 | - Improvement in Exercise capacity compared to placebo but not significant |
| 2019321 | Refractory angina | AD | 41 | - Improvement in cardiac symptoms but no change in exercise capacity |
| 2017324 | Heart failure | UC | 15 | - Improvements in LVEF compared to baseline at 3 months’follow-up |
| - No changes in left ventricular volumes | ||||
| 2020325 | Chronic ischemic cardiomyopathy | UC | 26 | - Improvement in LVEF, 6MWT, and NYHA |
| 2020326 | Chronic ischemic heart disease | UC | 32 | - Improvement in LVEF, MLHF, and NYHA |
| - Decrease infarct size |
6MWT 6-min walk test, CCS Canadian Cardiovascular Society, ESV end-systolic volume, LVEDV left ventricular end-diastolic chamber volume, LVEF left ventricular ejection fraction, LVESV left ventricular end-systolic volume, MACE major adverse cardiovascular events, MET metabolic equivalents, MLHF Minnesota Living with Heart Failure, MLHFQ Minnesota Living with Heart Failure Questionnaire, MVO2 maximal oxygen consumption, NYHA New York Heart Association, SPECT single photon emission computed tomography, TNF-α tumor necrosis factor alpha, WMSI wall motion score index